GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner

[1]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[2]  Wanqing Chen,et al.  Interactions between life expectancy and the incidence and mortality rates of cancer in China: a population-based cluster analysis , 2018, Cancer communications.

[3]  C. Cui,et al.  High G2 and S‐phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis , 2018, Cancer science.

[4]  Joshua M. Stuart,et al.  Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. , 2018, Cell.

[5]  J. R. Daum,et al.  GTSE1 regulates spindle microtubule dynamics to control Aurora B kinase and Kif4A chromokinesin on chromosome arms , 2017, The Journal of cell biology.

[6]  Eberhard Korsching,et al.  Interlaboratory variability of Ki67 staining in breast cancer. , 2017, European Journal of Cancer.

[7]  C. Qian.  At-home cancer screening: a solution for China and other developing countries with a large population and limited number of healthcare practitioners , 2017, Chinese journal of cancer.

[8]  Yanlin Huang,et al.  GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis , 2017, Scientific Reports.

[9]  M. Brackstone,et al.  Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients , 2017, Supportive Care in Cancer.

[10]  Monte D. Martin,et al.  GTSE1: a novel TEAD4-E2F1 target gene involved in cell protrusions formation in triple-negative breast cancer cell models. , 2017, OncoTarget.

[11]  B. Short.  GTSE1 leads cancer cells into CIN , 2016, The Journal of cell biology.

[12]  I. Ellis,et al.  Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer , 2016, Diagnostic Pathology.

[13]  Ansar Karimian,et al.  Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. , 2016, DNA repair.

[14]  Q. Ye,et al.  Silencing GTSE-1 expression inhibits proliferation and invasion of hepatocellular carcinoma cells , 2016, Cell Biology and Toxicology.

[15]  Joachim L. Schultze,et al.  Web-TCGA: an online platform for integrated analysis of molecular cancer data sets , 2016, BMC Bioinformatics.

[16]  A. Arance,et al.  Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.

[17]  Hanlee P. Ji,et al.  The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical–genomic driver associations , 2015, Genome Medicine.

[18]  S. André,et al.  Aneuploidy identifies subsets of patients with poor clinical outcome in grade 1 and grade 2 breast cancer. , 2015, Breast.

[19]  W. Yong,et al.  GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells , 2015, BMC Cancer.

[20]  Marius Raica,et al.  The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. , 2015, Anticancer research.

[21]  Chirayu Pankaj Goswami,et al.  PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.

[22]  E. Hirsch,et al.  PI3K/AKT signaling pathway and cancer: an updated review , 2014, Annals of medicine.

[23]  Karin M. Verspoor,et al.  Big Data in Medicine Is Driving Big Changes , 2014, Yearbook of Medical Informatics.

[24]  Stephen L. Abrams,et al.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention , 2014, Oncotarget.

[25]  M. Biffoni,et al.  TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells , 2014, Oncogene.

[26]  J. Chen,et al.  Alternative splicing in cancer: implications for biology and therapy , 2014, Oncogene.

[27]  Manuel Rodrigues,et al.  Place des technologies de séquençage haut débit en oncologie , 2013 .

[28]  M. Rodrigues,et al.  [Role of high-throughput sequencing in oncology]. , 2013, Bulletin du cancer.

[29]  A. Hyman,et al.  GTSE1 Is a Microtubule Plus-End Tracking Protein That Regulates EB1-Dependent Cell Migration , 2012, PloS one.

[30]  M. Campone,et al.  bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer , 2012, Breast Cancer Research and Treatment.

[31]  Jannik N. Andersen,et al.  Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.

[32]  J. Xing,et al.  Up-regulation of GTSE1 lacks a relationship with clinical data in lung cancer. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[33]  Shu Ichihara,et al.  Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.

[34]  Jorge S. Reis-Filho,et al.  Histological types of breast cancer: How special are they? , 2010, Molecular oncology.

[35]  C. Schneider,et al.  Human GTSE-1 Regulates p21CIP1/WAF1 Stability Conferring Resistance to Paclitaxel Treatment* , 2009, The Journal of Biological Chemistry.

[36]  J. Reis-Filho,et al.  Histological and molecular types of breast cancer: is there a unifying taxonomy? , 2009, Nature Reviews Clinical Oncology.

[37]  James M. Roberts,et al.  CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .

[38]  K. Raj,et al.  Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death , 2008, Cell cycle.

[39]  Carlos Caldas,et al.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.

[40]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[41]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[42]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[43]  J. Wunder,et al.  Cyclin D1 and p21 is elevated in the giant cells of giant cell tumors , 2006, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[44]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[45]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[46]  L. Marchionni,et al.  hGTSE-1 Expression Stimulates Cytoplasmic Localization of p53* , 2004, Journal of Biological Chemistry.

[47]  M. Lacroix,et al.  Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update , 2004, Breast Cancer Research and Treatment.

[48]  P. Sandy,et al.  The Cell Cycle-regulated Protein Human GTSE-1 Controls DNA Damage-induced Apoptosis by Affecting p53 Function* , 2003, Journal of Biological Chemistry.

[49]  R. Verardo,et al.  Cell‐cycle regulation of the p53‐inducible gene B99 , 2000, FEBS letters.

[50]  D. Lazarević,et al.  Cloning, chromosome mapping and functional characterization of a human homologue of murine gtse-1 (B99) gene. , 2000, Gene.

[51]  P. May,et al.  Twenty years of p53 research: structural and functional aspects of the p53 protein , 1999, Oncogene.

[52]  A. Goldhirsch,et al.  Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer , 1998 .

[53]  D. Lazarević,et al.  A novel p53‐inducible gene coding for a microtubule‐localized protein with G2‐phase‐specific expression , 1998, The EMBO journal.

[54]  A. Goldhirsch,et al.  Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. , 1998, European journal of cancer.

[55]  J. Gehl,et al.  Treatment of metastatic breast cancer with paclitaxel and doxorubicin. , 1995, Seminars in oncology.

[56]  J. Milner,et al.  Tumor suppressor p53: analysis of wild-type and mutant p53 complexes , 1991, Molecular and cellular biology.